Tayhs
2021-04-10
[开心]
UPDATE 1-Biotech firm Ginkgo in talks with Harry Sloan-led SPAC for over $20 bln deal
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":346368718,"tweetId":"346368718","gmtCreate":1617998807134,"gmtModify":1631891944479,"author":{"id":3569881740421551,"idStr":"3569881740421551","authorId":3569881740421551,"authorIdStr":"3569881740421551","name":"Tayhs","avatar":"https://static.tigerbbs.com/18c6192c150a987ab2c12c655cfdfabc","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":8,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p><span>[开心] </span><br></p></body></html>","htmlText":"<html><head></head><body><p><span>[开心] </span><br></p></body></html>","text":"[开心]","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/346368718","repostId":2126330720,"repostType":2,"repost":{"id":"2126330720","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1617985100,"share":"https://ttm.financial/m/news/2126330720?lang=&edition=full","pubTime":"2021-04-10 00:18","market":"us","language":"en","title":"UPDATE 1-Biotech firm Ginkgo in talks with Harry Sloan-led SPAC for over $20 bln deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2126330720","media":"Reuters","summary":"(Adds confirmation from source) By Krystal Hu April 9 (Reuters) - Biotech startup Ginkgo Biowork","content":"<html><body><p>(Adds confirmation from source)</p><p> By Krystal Hu</p><p> April 9 (Reuters) - Biotech startup Ginkgo Bioworks is in talks to go public through a merger with a blank-check firm backed by former Hollywood executives Harry Sloan and Jeff Sagansky, in a deal valued at about $20 billion, a person familiar with the matter said.</p><p> The company is in exclusive talks with Soaring Eagle Acquisition Corp for a potential business combination and a deal could be announced as soon as this month, the source said on Friday. </p><p> Soaring Eagle declined to comment on the matter. </p><p> Boston-based Ginkgo is backed by Bill Gates' private investment firm, Cascade Investment, and hedge fund Viking Global. It received a $1.1 billion loan from the U.S. government in November for COVID-19 testing and production of raw materials for therapies that may help address future pandemics.</p><p> Soaring Eagle, a special purpose acquisition company (SPAC), raised $1.7 billion through an initial public offering in February. </p><p> Sloan, a former chief executive officer of Metro Goldwyn Mayer, and Sagansky's former SPACs took gaming firms DraftKings Inc and <a href=\"https://laohu8.com/S/SKLZ\">Skillz Inc</a> public. </p><p> SPACs are shell companies that raise funds through an initial public offering to take a private company public through a merger at a later date.</p><p> (Reporting by Sohini Podder in Bengaluru; Editing by Shinjini Ganguli)</p><p>((sohini.podder@thomsonreuters.com;))</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>UPDATE 1-Biotech firm Ginkgo in talks with Harry Sloan-led SPAC for over $20 bln deal</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUPDATE 1-Biotech firm Ginkgo in talks with Harry Sloan-led SPAC for over $20 bln deal\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-04-10 00:18</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>(Adds confirmation from source)</p><p> By Krystal Hu</p><p> April 9 (Reuters) - Biotech startup Ginkgo Bioworks is in talks to go public through a merger with a blank-check firm backed by former Hollywood executives Harry Sloan and Jeff Sagansky, in a deal valued at about $20 billion, a person familiar with the matter said.</p><p> The company is in exclusive talks with Soaring Eagle Acquisition Corp for a potential business combination and a deal could be announced as soon as this month, the source said on Friday. </p><p> Soaring Eagle declined to comment on the matter. </p><p> Boston-based Ginkgo is backed by Bill Gates' private investment firm, Cascade Investment, and hedge fund Viking Global. It received a $1.1 billion loan from the U.S. government in November for COVID-19 testing and production of raw materials for therapies that may help address future pandemics.</p><p> Soaring Eagle, a special purpose acquisition company (SPAC), raised $1.7 billion through an initial public offering in February. </p><p> Sloan, a former chief executive officer of Metro Goldwyn Mayer, and Sagansky's former SPACs took gaming firms DraftKings Inc and <a href=\"https://laohu8.com/S/SKLZ\">Skillz Inc</a> public. </p><p> SPACs are shell companies that raise funds through an initial public offering to take a private company public through a merger at a later date.</p><p> (Reporting by Sohini Podder in Bengaluru; Editing by Shinjini Ganguli)</p><p>((sohini.podder@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SKLZ":"Skillz Inc","SRNGU":"Soaring Eagle Acquisition Corp.","DKNG":"DraftKings Inc."},"source_url":"http://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2126330720","content_text":"(Adds confirmation from source) By Krystal Hu April 9 (Reuters) - Biotech startup Ginkgo Bioworks is in talks to go public through a merger with a blank-check firm backed by former Hollywood executives Harry Sloan and Jeff Sagansky, in a deal valued at about $20 billion, a person familiar with the matter said. The company is in exclusive talks with Soaring Eagle Acquisition Corp for a potential business combination and a deal could be announced as soon as this month, the source said on Friday. Soaring Eagle declined to comment on the matter. Boston-based Ginkgo is backed by Bill Gates' private investment firm, Cascade Investment, and hedge fund Viking Global. It received a $1.1 billion loan from the U.S. government in November for COVID-19 testing and production of raw materials for therapies that may help address future pandemics. Soaring Eagle, a special purpose acquisition company (SPAC), raised $1.7 billion through an initial public offering in February. Sloan, a former chief executive officer of Metro Goldwyn Mayer, and Sagansky's former SPACs took gaming firms DraftKings Inc and Skillz Inc public. SPACs are shell companies that raise funds through an initial public offering to take a private company public through a merger at a later date. (Reporting by Sohini Podder in Bengaluru; Editing by Shinjini Ganguli)((sohini.podder@thomsonreuters.com;))","news_type":1,"symbols_score_info":{"DKNG":0.9,"SKLZ":0.9,"SRNGU":0.9}},"isVote":1,"tweetType":1,"viewCount":1296,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":6,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/346368718"}
精彩评论